Clinical Trial Detail

NCT ID NCT03309878
Title Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Lymphomas
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lymphoma

diffuse large B-cell lymphoma

Therapies

Pembrolizumab

Mogamulizumab + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.